Boston Scientific’s Watchman left atrial appendage closure device has been implanted in the first group of patients at Angiografia de Occidente in Cali, Colombia.
The device, for use in patients in atrial fibrillation who are at risk of stroke and are eligible for long-term oral anticoagulation therapy, is designed to prevent clots within the appendage from being dislodged into the bloodstream, reducing the risk of ischaemic stroke and systemic thromboembolism.
Go deeper with GlobalData
In the multicentre, randomised PROTECT AF clinical trial, the Watchman device was proved to be non-inferior to warfarin and demonstrated a 38% risk reduction for a combined measure of stroke, cardiovascular death and systemic embolism compared to long-term warfarin therapy.
The study also reported a 29% relative risk reduction in all strokes, and a 90% risk reduction in haemorrhagic stroke, compared with warfarin.
Angiografia de Occidente interventional cardiologist Bernardo Caicedo said that the device will provide safe and improved alternative for atrial fibrillation patients who cannot take long-term oral anticoagulants.
See Also:
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
